MX2009012091A - Antifungal formulation. - Google Patents
Antifungal formulation.Info
- Publication number
- MX2009012091A MX2009012091A MX2009012091A MX2009012091A MX2009012091A MX 2009012091 A MX2009012091 A MX 2009012091A MX 2009012091 A MX2009012091 A MX 2009012091A MX 2009012091 A MX2009012091 A MX 2009012091A MX 2009012091 A MX2009012091 A MX 2009012091A
- Authority
- MX
- Mexico
- Prior art keywords
- solution
- formulation
- concentration
- medicament
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 238000009472 formulation Methods 0.000 title claims description 18
- 230000000843 anti-fungal effect Effects 0.000 title claims description 7
- 229940121375 antifungal agent Drugs 0.000 title claims description 5
- 241000233866 Fungi Species 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 claims description 3
- 201000004647 tinea pedis Diseases 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000000855 fungicidal effect Effects 0.000 claims description 2
- 230000001408 fungistatic effect Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 4
- 239000011707 mineral Substances 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 2
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention consists in a solution of processed salts and minerals, which are beneficial to the skin and which may be used for removing fungi from the human skin, the invention being effective from the first application; this latter was probed by a user "A" and a user "B" (football player) and based on the scientific knowledge that the skin diseases are caused by mineral losses in our body, the use of the composition being beneficial and harmless, and recommended to treat said disease in a natural manner by being poured over the skin, this causing the regeneration of the cells and the removal of the fungus, as well as the malodour and the degeneration of the affected skin.
Description
ANTIMICTIC FORMULATION
DESCRIPTION
OBJECT OF THE INVENTION
The object of the present invention is related to the medical area, particularly it is a formulation with antifungal properties, which is useful in the treatment of multiple diseases related to fungal infection.
BACKGROUND
Currently there are numerous antifungal formulations, some inhibit the growth of fungi (fungistatics), while others provide a fungicidal effect by eliminating them. - The disadvantages of some or most of them is that the time of action and effectiveness of the most recommended is seven days, but do not disclose the procedure and the activity that the test subjects do, there will always be a doubt that on the test days they are not forced to wear a normal routine like fitting the same shoes and socks, walking or working as they regularly do in terms of costs for the lower middle class the price is prohibitive, as for chemical compounds those of these medications none occurs naturally are precisely that compounds that do not replenish the loss that the body presents and this is the main cause of any disease.
The biggest advantage of our formulation in relation to those already known is that in the first application following the instructions to the letter it has been proven that in
a humid environment like the one of the northeast of the Mexican republic with a normal action routine, using the same footwear, the same pairs (several) of socks and practicing four days a week a demanding sport for the feet as it is the fotball soccer, the subject A (my son) and the subject B (a server) after four months of daily observation we have verified that the bad smell disappeared, therefore the fungus also. To conclude our formulation is based one hundred percent on mineral products that are basic in the human body, which occur in nature as a result the price to the public is more accessible.
DETAILED DESCRIPTION OF THE INVENTION
The present invention comprises a formulation with antifungal or antifungal properties, which is different and novel. The composition of said formulation is described below.
The antifungal formulation, object of the present invention consists of a set of pharmaceutically acceptable salts and minerals that nourish, and exfoliate the infected cells with fungi.
The formulation comprises:
to. Monohydrate glucose in a concentration of 2.5 to 4.25g / 100mL, with the optimal 4.5g / 100mL lOOmL of solution >
b. Sodium chloride at a concentration of 538mg / 100mL lOOmL of solution c. Calcium chloride dihydrate at a concentration of 25.7mg / 100mL lOOmL of solution
d. Magnesium chloride hexahydrate in cradle concentration of 5.06mg / 100mL lOOmL of solution
and. Sodium lactate in a concentration of 448mg / 100mL of solution
All these ingredients are added and dissolved in bidistilled and demineralized water by gauging until reaching the aforementioned concentrations.
Among others, this formulation presents the following chemical characteristics: pH from 5.0 to 5.6; 486 milliosmoles per liter; 132 milli equivalents of sodium; 0.2 milli equivalents of magnesium, 40 milli equivalents of lactate; 3.5 milli equivalents of calcium; 96 milli equivalents of chloride.
The formulation described above can be presented as a solution, cream, gel, lyophilized powder and other presentations that could be obtained to adapt its application for topical use in the affected area.
The above-described formula which is the subject of the present invention, is an existing formulation which is used in the field of nephrology, particularly as a solution for peritoneal dialysis. Based on observation and experimentation, we propose this new use or novel application of the formula in the treatment and / or topical prevention of athlete's foot and other dermatological infections caused by fungi.
Claims (7)
1 . Use of an antifungal formulation which includes glucose monohydrate in a concentration of 2.5 to 4.25g / 100mL, sodium chloride in a concentration of 538mg / 100mL lOOmL of solution, calcium chloride dihydrate in a concentration of 25.7mg / 100mL lOOmL of solution , Magnesium chloride hexahydrate in cradle concentration of 5.06mg / 100mL lOOmL of solution, sodium lactate in a concentration of 448mg / 100mL of solution for the Preparation of a medicine with fungicidal and fungistatic properties.
2. Use according to claim 1 wherein the formulation is useful in the treatment of athlete's foot
3. Use according to claim 1 wherein the formulation is useful for the treatment of infections caused by fungi in mammals
4. Use of a medicament whose active ingredient is the formulation described and claimed in the above, for the treatment of athlete's foot.
5. Use of a medicament according to claim 4 wherein this is useful in the treatment of infections caused by fungi in mammals.
6. Use of a medicament according to claim 4 wherein it can be presented in the form of a solution, cream, gel, powder and other known pharmaceutical presentations.
7. Use of a medicament in accordance with claim 4 wherein its application is topical. Use of a medicament according to claim 4 wherein said medicament contains the formulation described in claims 1 to 3 as an active ingredient together with pharmaceutically acceptable excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2009012091A MX2009012091A (en) | 2009-11-09 | 2009-11-09 | Antifungal formulation. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2009012091A MX2009012091A (en) | 2009-11-09 | 2009-11-09 | Antifungal formulation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012091A true MX2009012091A (en) | 2011-05-23 |
Family
ID=44676148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012091A MX2009012091A (en) | 2009-11-09 | 2009-11-09 | Antifungal formulation. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX2009012091A (en) |
-
2009
- 2009-11-09 MX MX2009012091A patent/MX2009012091A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6360267B2 (en) | Antifungal composition for the treatment of skin and nails | |
| EA018425B1 (en) | Pharmaceutical, disinfectant or preservation extract of trigonella foenum-graecum, method for preparing and use thereof | |
| US10864188B2 (en) | Anti-microbial composition | |
| CA2864910C (en) | Antifungal compositions for the treatment of skin and nails | |
| KR20070092095A (en) | Disinfection compositions and methods for their preparation and use | |
| WO2014159930A1 (en) | Antifungal compositions for the treatment of secondary skin and nail infections | |
| EP3378475B1 (en) | Composition and kit for the use in the prevention of recurrent onychomycosis | |
| CN107753504A (en) | For pain, itch and the strontium of inflammation based composition and use thereof in packaging and composite | |
| CN1183934C (en) | Disinfectant | |
| US6998109B1 (en) | Emu-based formulations with lidocaine for wound treatment by inhibiting microbial activity | |
| MX2009012091A (en) | Antifungal formulation. | |
| ES2971823T3 (en) | Enhancement of the antibacterial actions of a depsipeptide antibiotic through synergistic amounts of boric acid | |
| US20160106797A1 (en) | Topical treatment of shingles | |
| US7476379B1 (en) | Emu-based formulations for the treatment of damaged skin by inhibiting microbial and fungal activity | |
| US20250352515A1 (en) | Topical formulations | |
| CN108635362A (en) | A kind of pharmaceutical composition for treating diabetes | |
| CA2479381C (en) | A use of treatment for fungal infections with a synergistic formulation of antifungal agent, menthol and menthyl acetate | |
| CN113116984A (en) | Herbal formula for treating beriberi | |
| CN107823621A (en) | A kind of double-formulation controls tinea pedis composition and its application method | |
| KR20110069303A (en) | Athlete's foot medicine | |
| CN1883568A (en) | Chinese medicinal ointment for treating beriberi | |
| CN104758418A (en) | A foot nursing essence liquid and a preparing method thereof | |
| JP2007204461A (en) | Fungicidal disinfectant used as therapeutic agent for nail trichophytosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |